Skip to search formSkip to main contentSkip to account menu

filgotinib

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

GLPG0634

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
.
OBJECTIVES We assessed the relative efficacy and safety of once-daily administration of 100 and 200 mg filgotinib (a JAK1… 
2019
2019
THU0117 PHARMACOKINETICS AND SHORT-TERM SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT
Background Filgotinib (FIL) is an oral selective Janus kinase 1 (JAK1) inhibitor being developed to treat inflammatory diseases… 
Review
2018
Review
2018
Filgotinib for the treatment of Crohn’s disease
ABSTRACT Introduction: Inflammatory bowel diseases, such as Crohn’s disease (CD) and ulcerative colitis (UC), are widespread… 
2018
2018
Treatment Perspectives in Crohn’s Disease
Background: Crohn’s disease (CD) is a chronic immune-mediated disorder of the gastrointestinal tract. The pathophysiological… 
2017
2017
Effects of hypnotic bromovalerylurea on microglial BV2 cells.
2017
2017
OP0161 The JAK1 selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis
Background Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease characterized by the association of… 
2017
2017
THU0206 The jak1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients
Background JAK1, 2, 3 and TYK2 are cytoplasmic tyrosine kinases that mediate intracellular signaling of many cytokines and growth… 
2016
2016
THU0173 Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor Is Effective as Monotherapy in Patients with Active Rheumatoid Arthritis: Results from A 24-Week Phase 2B Dose Ranging Study
Background Filgotinib (GLPG0634) is a novel oral, selective JAK1 inhibitor that was evaluated in a 24-week phase 2B study as… 
2016
2016
THU0167 The Effect of Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2b Dose Ranging Studies
Background Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that showed rapid and sustained… 
2016
2016
812c Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor, Induces Clinical Remission in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 2 FITZROY Study Interim Analysis
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)